Oncorus, Inc. (ONCR) files for IPO.

The IPO of Oncorus, Inc. will take place on October 1, 2020. Oncorus is a clinical stage biopharmaceutical company focused on developing the next-generation viral immunotherapies to improve outcomes for cancer patients. Using its two patented platforms, the company is developing a pipeline of intratumorally and intravenously administered product candidates to selectively attack and kill tumor cells and to stimulate multiple arms of the immune system against tumors.
The company’s expected value after the IPO will be $421 million.
Listed underwriters of the IPO are Jefferies, Evercore ISI and Piper Sandler.